Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics' Long-Term Deferred Tax history spans 1 years, with the latest figure at $87.6 million for Q4 2018.

  • For Q4 2018, Long-Term Deferred Tax changed N/A year-over-year to $87.6 million; the TTM value through Dec 2018 reached $87.6 million, changed N/A, while the annual FY2018 figure was $87.6 million, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $87.6 million in Q4 2018 per CTMX's latest filing.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $87.6 million in Q4 2018 to a low of $87.6 million in Q4 2018.